Abbott Adds IgM Test To COVID-19 Diagnostic Line-Up
Executive Summary
The FDA has granted an emergency use authorization for a COVID-19 IgM antibody blood test that runs on Abbott’s Architect and Alinity platforms.
You may also be interested in...
Abbott’s 3Q $8.9Bn Sales Beat Wall Street Consensus, Medtech Sales Up 3.4%
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
FDA Grants EUA For Access Bio’s Lateral Flow COVID-19 Antigen Test
Access Bio joins Abbott as the second company with FDA authorization to distribute PCR, antigen and antibody tests for COVID-19.
Device Week, 21 January 2022 – J.P. Morgan Health Care Conference Highlights; Spotlight PneumoWave
On this week’s podcast, Medtech Insight's Reed Miller, Marion Webb and Barnaby Pickering provide a recap of our J.P. Morgan Health Care conference coverage including Abbott, Dexcom, Zimmer Biomet and Nuvasive and spotlight Scottish company PneumoWave.